• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

亚洲部分国家和地区针对罕用药开发的激励措施以及对我国的启示

褚淑贞, 李伟霞

褚淑贞, 李伟霞. 亚洲部分国家和地区针对罕用药开发的激励措施以及对我国的启示[J]. 中国药科大学学报, 2014, 45(1): 125-128. DOI: 10.11665/j.issn.1000-5048.20140123
引用本文: 褚淑贞, 李伟霞. 亚洲部分国家和地区针对罕用药开发的激励措施以及对我国的启示[J]. 中国药科大学学报, 2014, 45(1): 125-128. DOI: 10.11665/j.issn.1000-5048.20140123
shu
CHU Shuzhen, LI Weixia. Incentive measures for orphan drug R&D in several Asian countries and regions and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2014, 45(1): 125-128. DOI: 10.11665/j.issn.1000-5048.20140123
Citation: CHU Shuzhen, LI Weixia. Incentive measures for orphan drug R&D in several Asian countries and regions and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2014, 45(1): 125-128. DOI: 10.11665/j.issn.1000-5048.20140123
shu

亚洲部分国家和地区针对罕用药开发的激励措施以及对我国的启示

  • 中国药科大学国际医药商学院

Incentive measures for orphan drug R&D in several Asian countries and regions and the enlightenment to China

摘要

    摘要
  • 摘要: 通过文献分析以及对比研究方法，总结日本、韩国以及中国台湾地区在罕用药开发方面的激励措施。研究发现，日本对罕用药开发的激励力度最大，韩国和中国台湾地区的激励措施相对保守，但均对罕用药的开发起到了促进作用。通过借鉴其政策实施经验，为制定中国罕用药开发的激励措施提出建议。
    Abstract: Literature review and comparative analysis were employed in this study to summarize the incentivemeasures for facilitating orphan drugs R&D in Japan, South Korea and Taiwan region of China. It was found that the incentive strength in Japan was the greatest among the countries and region above, while those in South Korea and Taiwan region were relatively conservative. Yet all these incentives had promoted the development of orphan drugs and their successful implementation experience have provide suggestions for the establishment of incentive measures for facilitating orphan drugs R&D in China.
    • HTML全文
    • 参考文献(14)
  • [1] 张舵,王晓洁.罕见病发病率上升“孤儿药”产业亟待政策支持[N].中国医药报,2013-01-08(7).
    [2] MHLW.指定年度別の承認取得、開発、指定取消の状況[EB/OL].(2013-07-25)http://www.nibio.go.jp/shinko/s_jyokyo.html.
    [3] Song PP,Gao JJ,Inagaki Y,et al.Rare diseases,orphan drugs,and their regulation in Asia:Current status and future perspectives[J].Intractable Rare Dis Re,2012,1(1):3-9.
    [4] 邵建国.亚洲:“孤儿药”的乐土[N].医药经济报,2007-05-14(3).
    [5] Lee S,Lee JI.Rare disease research and orphan drug development[J].Kor J Clin Pharm,2013, 23(1):8-9.
    [6] How specific legislation for rare diseases and orphan drugs is changing life for some patients in Taiwan[EB/OL].http://www.orpha.net/actor/EuropaNews/2009/doc/Taiwan.pdf
    [7] Department of Health,TAIWAN.List of Orphan Drug[EB/OL].[2012-01-31].http://www.doh.gov.tw.
    [8] Tao Y,Bu YF,Zhang C,et al.Orphan drug management systems in Japan(日本的罕用药管理制度)[J].Chin Pharm J(中国药学杂志),2002,37(6):468-471.
    [9] Gong SW. Management strategies of improving orphan drugs accessibility in China(促进我国罕见病患者药品可及性的管理策略研究)[D].Wuhan:Huazhong University of Science and Technology,2008.
    [10] Tang JY,Zhao XY.Contrastive analysis of abroad orphan drug management systems and suggestions for China [J].Chin New Drug J(中国新药杂志),2013, 22(14):1 638-1 642.
    [11] Xin XX,Guan XD,Chen J,et al.Analysis and comparison of foreign and domestic orphan drug registration policies [J].Chin Pharm J(中国药学杂志),2013,48(15):1 323-1 327.
    [12] Cheng Y.The Dilemma and outlet of the legal institution of rare disease [J].Hebei Law Sci(河北法学),2011,29(5):10-17.
    [13] Wu SY, Zhang K. Opportunities and challenges in strategies establishement of rare disease research and prevention in China(中国建立罕见病研究和防治策略的机遇与未来挑战)[J].Shanghai Med Pharm J(上海医药),2011,32(10):502-504.
    [14] 李天舒.“孤儿药”研发困境等待破局[N].健康报,2011-10-25(5).
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1121
  • HTML全文浏览量:  1
  • PDF下载量:  1896
  • 被引次数: 0
出版历程
  • 刊出日期:  2014-02-24

目录

摘要
HTML全文
    参考文献(14)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：323943

    x 关闭 永久关闭